US 7,732,139 B2Granted

Multiple SNP for diagnosing cardiovascular disease, microarray and kit comprising the same, and method of diagnosing cardiovascular disease using the same

AssigneeSamsung Electronics Co., Ltd.

InventorsSeung-Hak Choi, Yun-sun Nam, Jae-Heup Kim, Kyung-Hee Park, Yeon-Su Lee, Hyo-jeong Jeon, Ok-ryul Song, Tae-jin Ahn, Kyu-sang Lee

Life of this patent

Estimating the term…

Abstract

A multiple single nucleotide polymorphism (multi-SNP) marker for cardiovascular disease diagnosis and a method of diagnosing cardiovascular disease are provided. Also, sets of polynucleotides, a microarray, and a kit including the microarray are provided.

Claims6

Dependent claims

A microarray consisting of a set of polynucleotides and optionally, a substrate on which the set of polynucleotides is immobilized, the set of polynucleotides consisting of

(a) at least one isolated polynucleotide selected from
(i) a polynucleotide consisting of 15 to 100 contiguous bases of SEQ ID NO:
2 wherein the 15 to 100 contiguous bases comprises C at the 101st position in SEQ ID NO:
2,
(ii) a polynucleotide consisting of the complement of the polynucleotide of (i);
(iii) a polynucleotide consisting of 15 to 100 contiguous bases of SEQ ID NO:
2 wherein the 15 to 100 contiguous bases comprises T at the 101st position in SEQ ID NO:
2, and
(iv) a polynucleotide consisting of the complement of the polynucleotide of (iii);
(b) at least one isolated polynucleotide selected from
(v) a polynucleotide consisting of 15 to 100 contiguous bases of SEQ ID NO:
3 wherein the 15 to 100 contiguous bases comprises G at the 101st position in SEQ ID NO:
3,
(vi) a polynucleotide consisting of the complement of the polynucleotide of (v),
(vii) a polynucleotide consisting of 15 to 100 contiguous bases of SEQ ID NO:
3 wherein the 15 to 100 contiguous bases comprises T at the 101st position in SEQ ID NO:
3, and
(viii) a polynucleotide consisting of the complement of the polynucleotide of (vii);
(c) at least one isolated polynucleotide selected from
(ix) a polynucleotide consisting of 15 to 100 contiguous bases of SEQ ID NO:
25, wherein the 15 to 100 contiguous bases comprises C at the 101st position in SEQ ID NO:
25,
(x) a polynucleotide consisting of the complement of the polynucleotide of (ix),
(xi) a polynucleotide consisting of 15 to 100 contiguous bases of SEQ ID NO:
25, wherein the 15 to 100 contiguous bases comprises T at the 101st position in SEQ ID NO:
25, and
(xii) a polynucleotide consisting of the complement of the polynucleotide of (xi);
and optionally
(d) at least one isolated polynucleotide consisting of 15 to 100 contiguous bases of a sequence selected from
(xiii) SEQ ID NOS:
1, 4-24, and 26-35, wherein the 15 to 100 contiguous bases comprises a base at a single nucleotide polymorphism (SNP) position in the selected sequence, wherein the SNP is positioned at the 76th nucleotide in SEQ ID NO:
4, the 85th nucleotide in SEQ ID NO:
8, the 51St nucleotide in SEQ ID NO:
9, the 35th nucleotide in SEQ ID NO:
10, the 85th nucleotide in SEQ ID NO:
19 or the 101st nucleotide in SEQ ID NOS:
1, 5-7, 11-18, 20-24, and 26-35;
or
(xiv) a polynucleotide consisting of the complement of the polynucleotide of (xiii).

36 more elements

A kit comprising a microarray consisting of a substrate and a set of polynucleotides immobilized on the substrate, the set of polynucleotides consisting of

(a) at least one isolated polynucleotide selected from
(i) a polynucleotide consisting of 15 to 100 contiguous bases of SEQ ID NO:
2 wherein the 15 to 100 contiguous bases comprises C at the 101st position in SEQ ID NO:
2,
(ii) a polynucleotide consisting of the complement of the polynucleotide of (i);
(iii) a polynucleotide consisting of 15 to 100 contiguous bases of SEQ ID NO:
2 wherein the 15 to 100 contiguous bases comprises T at the 101st position in SEQ ID NO:
2, and
(iv) a polynucleotide consisting of the complement of the polynucleotide of (iii);
(b) at least one isolated polynucleotide selected from
(v) a polynucleotide consisting of 15 to 100 contiguous bases of SEQ ID NO:
3 wherein the 15 to 100 contiguous bases comprises G at the 101st position in SEQ ID NO:
3,
(vi) a polynucleotide consisting of the complement of the polynucleotide of (v),
(vii) a polynucleotide consisting of 15 to 100 contiguous bases of SEQ ID NO:
3 wherein the 15 to 100 contiguous bases comprises T at the 101st position in SEQ ID NO:
3, and
(viii) a polynucleotide consisting of the complement of the polynucleotide of (vii);
(c) at least one isolated polynucleotide selected from
(ix) a polynucleotide consisting of 15 to 100 contiguous bases of SEQ ID NO:
25, wherein the 15 to 100 contiguous bases comprises C at the 101st position in SEQ ID NO:
25,
(x) a polynucleotide consisting of the complement of the polynucleotide of (ix),
(xi) a polynucleotide consisting of 15 to 100 contiguous bases of SEQ ID NO:
25, wherein the 15 to 100 contiguous bases comprises T at the 101st position in SEQ ID NO:
25, and
(xii) a polynucleotide consisting of the complement of the polynucleotide of (xi);
and optionally
(d) at least one isolated polynucleotide consisting of 15 to 100 contiguous bases of a sequence selected from
(xiii) SEQ ID NOS:
1, 4-24, and 26-35, wherein the 15 to 100 contiguous bases comprises a base at a single nucleotide polymorphism (SNP) position in the selected sequence, wherein the SNP is positioned at the 76th nucleotide in SEQ ID NO:
4, the 85th nucleotide in SEQ ID NO:
8, the 51St nucleotide in SEQ ID NO:
9, the 35th nucleotide in SEQ ID NO:
10, the 85th nucleotide in SEQ ID NO:
19 or the 101st nucleotide in SEQ ID NOS:
1, 5-7, 11-18, 20-24, and 26-35;
or
(xiv) a polynucleotide consisting of the complement of the polynucleotide of (xiii).

36 more elements

A set of polynucleotides, wherein the set consists of

(a) at least one isolated polynucleotide selected from
(i) a polynucleotide consisting of 15 to 100 contiguous bases of SEQ ID NO:
2 wherein the 15 to 100 contiguous bases comprises C at the 101st position in SEQ ID NO:
2,
(ii) a polynucleotide consisting of the complement of the polynucleotide of (i);
(iii) a polynucleotide consisting of 15 to 100 contiguous bases of SEQ ID NO:
2 wherein the 15 to 100 contiguous bases comprises T at the 101st position in SEQ ID NO:
2, and
(iv) a polynucleotide consisting of the complement of the polynucleotide of (iii);
(b) at least one isolated polynucleotide selected from
(v) a polynucleotide consisting of 15 to 100 contiguous bases of SEQ ID NO:
3 wherein the 15 to 100 contiguous bases comprises G at the 101st position in SEQ ID NO:
3,
(vi) a polynucleotide consisting of the complement of the polynucleotide of (v),
(vii) a polynucleotide consisting of 15 to 100 contiguous bases of SEQ ID NO:
3 wherein the 15 to 100 contiguous bases comprises T at the 101st position in SEQ ID NO:
3, and
(viii) a polynucleotide consisting of the complement of the polynucleotide of (vii);
(c) at least one isolated polynucleotide selected from
(ix) a polynucleotide consisting of 15 to 100 contiguous bases of SEQ ID NO:
25, wherein the 15 to 100 contiguous bases comprises C at the 101st position in SEQ ID NO:
25,
(x) a polynucleotide consisting of the complement of the polynucleotide of (ix),
(xi) a polynucleotide consisting of 15 to 100 contiguous bases of SEQ ID NO:
25, wherein the 15 to 100 contiguous bases comprises T at the 101st position in SEQ ID NO:
25, and
(xii) a polynucleotide consisting of the complement of the polynucleotide of (xi);
and optionally
(d) at least one isolated polynucleotide consisting of 15 to 100 contiguous bases of a sequence selected from
(xiii) SEQ ID NOS:
1, 4-24, and 26-35, wherein the 15 to 100 contiguous bases comprises a base at a single nucleotide polymorphism (SNP) position in the selected sequence, wherein the SNP is positioned at the 76th nucleotide in SEQ ID NO:
4, the 85th nucleotide in SEQ ID NO:
8, the 51St nucleotide in SEQ ID NO:
9, the 35th nucleotide in SEQ ID NO:
10, the 85th nucleotide in SEQ ID NO:
19 or the 101st nucleotide in SEQ ID NOS:
1, 5-7, 11-18, 20-24, and 26-35;
or
(xiv) a polynucleotide consisting of the complement of the polynucleotide of (xiii).

36 more elements

Dependencies are inferred from the claim text.

Facts

Application: 11/435,662Filed 17 May 2006
Priority: KR 10-2005-004165318 May 2005
Published: US 2006/0263815 A123 Nov 2006
Granted: 8 Jun 2010
Term ends: Not estimatedThe source records don’t support an estimate.

Classification4 codes

C12Q 1/6886
For diseases caused by alterations of genetic material: for cancer
C12Q 2600/156
Oligonucleotides characterized by their use: polymorphic or mutational markers
C12Q 2600/172
Oligonucleotides characterized by their use: haplotypes
C12Q
Measuring or testing processes involving enzymes, nucleic acids or microorganisms

Family

US 2006/0263815 A1Pre-grant publication · published 23 Nov 2006
US 7,732,139 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

A microarray consisting of a set of polynucleotides and optionally, a substrate on which the set of polynucleotides is immobilized, the set of polynucleotides consisting of

(a) at least one isolated polynucleotide selected from
(i) a polynucleotide consisting of 15 to 100 contiguous bases of SEQ ID NO:
2 wherein the 15 to 100 contiguous bases comprises C at the 101st position in SEQ ID NO:
2,
(ii) a polynucleotide consisting of the complement of the polynucleotide of (i);
(iii) a polynucleotide consisting of 15 to 100 contiguous bases of SEQ ID NO:
2 wherein the 15 to 100 contiguous bases comprises T at the 101st position in SEQ ID NO:
2, and
(iv) a polynucleotide consisting of the complement of the polynucleotide of (iii);
(b) at least one isolated polynucleotide selected from
(v) a polynucleotide consisting of 15 to 100 contiguous bases of SEQ ID NO:
3 wherein the 15 to 100 contiguous bases comprises G at the 101st position in SEQ ID NO:
3,
(vi) a polynucleotide consisting of the complement of the polynucleotide of (v),
(vii) a polynucleotide consisting of 15 to 100 contiguous bases of SEQ ID NO:
3 wherein the 15 to 100 contiguous bases comprises T at the 101st position in SEQ ID NO:
3, and
(viii) a polynucleotide consisting of the complement of the polynucleotide of (vii);
(c) at least one isolated polynucleotide selected from
(ix) a polynucleotide consisting of 15 to 100 contiguous bases of SEQ ID NO:
25, wherein the 15 to 100 contiguous bases comprises C at the 101st position in SEQ ID NO:
25,
(x) a polynucleotide consisting of the complement of the polynucleotide of (ix),
(xi) a polynucleotide consisting of 15 to 100 contiguous bases of SEQ ID NO:
25, wherein the 15 to 100 contiguous bases comprises T at the 101st position in SEQ ID NO:
25, and
(xii) a polynucleotide consisting of the complement of the polynucleotide of (xi);
and optionally
(d) at least one isolated polynucleotide consisting of 15 to 100 contiguous bases of a sequence selected from
(xiii) SEQ ID NOS:
1, 4-24, and 26-35, wherein the 15 to 100 contiguous bases comprises a base at a single nucleotide polymorphism (SNP) position in the selected sequence, wherein the SNP is positioned at the 76th nucleotide in SEQ ID NO:
4, the 85th nucleotide in SEQ ID NO:
8, the 51St nucleotide in SEQ ID NO:
9, the 35th nucleotide in SEQ ID NO:
10, the 85th nucleotide in SEQ ID NO:
19 or the 101st nucleotide in SEQ ID NOS:
1, 5-7, 11-18, 20-24, and 26-35;
or
(xiv) a polynucleotide consisting of the complement of the polynucleotide of (xiii).

36 more elements

Facts

Application

11/435,662Filed 17 May 2006

Priority

KR 10-2005-004165318 May 2005

Published

US 2006/0263815 A123 Nov 2006

Granted

8 Jun 2010

Term ends

Not estimatedThe source records don’t support an estimate.

Classification4 codes

C12Q 1/6886
For diseases caused by alterations of genetic material: for cancer
C12Q 2600/156
Oligonucleotides characterized by their use: polymorphic or mutational markers
C12Q 2600/172
Oligonucleotides characterized by their use: haplotypes
C12Q
Measuring or testing processes involving enzymes, nucleic acids or microorganisms